Aims The objective of this study was to compare the pharmacokinetics, safety and tolerability of the antiepileptic drug felbamate in young and elderly healthy vounteers. Methods The single and multiple dose pharmacokinetics of felbamate were examined in an open-label two-dose level parallel group study in 24 elderly (66 to 78-yearold) and 11 young (18 to 45-year-old) healthy volunteer subjects. Pharmacokinetics were determined from blood samples obtained over 120 h after administration of single 600 mg or 1200 mg doses, and after multiple doses of 600 mg or 1200 mg administered every 12 h. Safety and tolerability were assessed through laboratory tests, ECGs, vital signs and reported adverse events. Results Single dose felbamate pharmacokinetic parameters differed between young and elderly subjects; compared with young subjects, elderly subjects had lower mean clearance (31.2 vs 25.1 ml min −1 ; 90% CI −11.4 to −0.9; P=0.02) and a trend towards a greater half-life (18.6 vs 21.0 h; 90% CI −0.6 to 5.4; P=0.11). Mean AUC and C max values were also higher in elderly subjects. No gender differences were noted for weight-adjusted pharmacokinetic variables. Felbamate was less well tolerated in elderly subjects compared with young subjects, as shown by higher rates of adverse event reporting and dropouts at the higher dose level. This may be due to age-related pharmacokinetic differences, to the rapid dose titration schedule used in this study, and/or to altered sensitivity to felbamate's pharmacodynamic effects. Conclusions These findings imply that elderly subjects require lower initial dosing and slower dose titration of felbamate than non-elderly subjects.
Introduction new antiepileptic agents such as felbamate in this population. Felbamate (2-phenyl-1, 3-propanediol dicarbamate) is a chemically unique orally active antiepileptic agent which Methods has demonstrated anticonvulsant activity in patients with partial seizures with or without secondary generalization and Thirty-five male and female subjects were enrolled into this Lennox-Gastaut syndrome [1, 2] . Pharmacokinetic studies open-label, single and multiple dose, parallel group study. in man have shown that following oral administration of Included were 24 elderly volunteers (mean age 71.3 years; [ 14 C] felbamate, greater than 90% of radioactivity is range 66-78 years; mean weight 72.3 kg; range eliminated in urine indicating that felbamate is well absorbed 51.0-91.9 kg; 12 females, 12 males), and 11 young volunteers [3] . Felbamate is eliminated by both renal excretion and (mean age 28.8 years; range 18-45 years; mean weight hepatic metabolism, with formation of para-and 2-70.2 kg; range 53.4-92.5 kg; four females, seven males). All hydroxymetabolites (which are subsequently conjugated) subjects were determined to be in good health through and a monocarbamate metabolite [3] . Felbamate has a medical history, physical examination and laboratory tests. volume of distribution of <1 l kg −1 , and does not bind This study was approved by a local ethics committee, and extensively to plasma proteins [4] . each subject provided written informed consent prior to Epidemiological studies on epilepsy have demonstrated participation. that the incidence of seizures increases after 60 years of age
The study duration was 14 days. All subjects received a [5], possibly as a result of increased vulnerability to disorders single dose of felbamate on Day 1, followed by multiple that induce seizures such as reduced haemostatic mechanisms, blood sampling for pharmacokinetic assessment through to brain tumours, cerebrovascular accidents and infections. 120 h post dose (Day 6). were for noted for CL/F and CLr (both of which were approximately 20% lower in elderly compared with young with respect to linearity, specificity, limit of quantitation, precision and accuracy. Inter-and intraassay CVs were less subjects) and AUC (which was 20% higher in elderly compared with young subjects for the high dose group). than 5% and less than 3.8% respectively over the concentration range 0.1-50 mg ml −1 . The limits of quantitation Consistent but non-significant trends were noted for AUC (low dose group), C max and t 1/2,z , with higher values in (LOQ) were 0.1 mg ml −1 in plasma and 1 mg ml −1 in urine.
Physical examinations, ECGs, safety laboratory tests and elderly subjects. In contrast, multiple dose pharmacokinetic parameters (C max , AUC and CL/F ) were generally similar recordings of vital signs were completed at screening, at various times during the study and at the completion of the in elderly and young subjects. Only five subjects were able to tolerate dose escalation to 3600 mg (four young male and multiple dose period. Throughout the study, the volunteers were continuously observed and questioned for the occurone elderly male subjects). Mean (s.d.) C max and AUCt values for these five subjects were 100 (14) ng ml −1 and rence of adverse events.
Plasma concentrations above the LOQ were used for 745 (117) ng ml −1 h, respectively. Mean (s.d.) creatinine clearance values in young and elderly subjects were 82 (22) pharmacokinetic analysis using model independent methods [7] . The maximum plasma concentration (C max ) was the and 55 (15) Single dose clearance and t 1/2,z data from all subjects were slope of the log-linear terminal portion of the plasma concentration-time curve using linear regression. The combined to examine the effects of gender on single dose pharmacokinetic parameters. Statistically significant differterminal phase half-life (t 1/2,z ) was calculated as 0.693/l z . The areas under the plasma concentration-time curve from ences were noted between males and females for CL/F and CLr (approximately 20-25% lower for females compared time zero-to the final quantifiable concentration, AUC(0,t ) (on day 1 only), and over the dosing interval t, AUC(t), with males); however there were no gender differences for t 1/2,z and bodyweight-adjusted CLr (Table 2) . were calculated using the linear trapezoidal rule (t=12 h for multiple dosing). For single dose data, the value of There were no clinically relevant abnormalities or changes in the clinical laboratory tests, physical examinations, ECGs AUC(0,t ) was extrapolated to infinity by the equation: AUC=AUC(0,t)+Ct/l z , where Ct was the estimated or vital signs in any subjects during the study. Overall, 30 of the 35 subjects (86%) reported at least one adverse event. concentration determined from linear regression at time t. Apparent total body clearance (CL/F) after single dosing
The most frequently reported adverse events were headache (66%), nausea (66%), dizziness (51%), constipation (34%), was calculated as dose/AUC, and after multiple dosing as dose/AUC(t). The apparent volume of distribution ( V z ) somnolence (31%), ataxia (26%), insomnia (26%), impaired concentration (23%), dry mouth (17%), fatigue (17%), was calculated from the single dose data as (Dose/AUC)/l z . Renal clearance (CLr) was calculated from the single dose vomiting (14%), apathy (14%), confusion (11%), and pharyngitis (11%), and all were rated as mild to moderate in data by the following equation: CLr=Ae/AUC, where Ae was the amount of felbamate excreted into the urine during severity. The incidence of adverse events in the high dose group (21/21, 100%) was greater than that of the low dose a dosing interval. The effects of age and gender on pharmacokinetic variables were assessed by confidence group (9/14, 64%). The range of adverse events in the high dose group was more extensive than those in the low dose estimated to be approximately 50% [10] . Similar effects have been seen for benzodiazepines which undergo oxidative group, although their nature (central nervous system and gastrointestinal in origin) was similar. In the low dose group metabolism (e.g. diazepam) [9] . In contrast, age-related pharmacokinetic changes have been shown to be relatively the incidence of subjects reporting adverse events increased with increasing age; 33% in subjects aged 18-45 years, 50% minor for the newer AEDs lamotrigine, vigabatrin and gabapentin [11] [12] [13] , which are eliminated unchanged or in 66-70 year olds, 75% in 71-75 year olds, and 100% in subjects aged 76 years and over. The rate of adverse event which undergo primarily Phase 2 metabolism. The pattern of elimination of felbamate is not yet fully elucidated, but it reporting was slightly higher in females (4/6; 67%) compared with males (4/8; 50%) in the low dose group.
is renally excreted unchanged and also undergoes some oxidative metabolism [3]. Thus age-related changes in these Overall, 16 of the 35 (46%) subjects discontinued prior to Day 14. Fifteen of the 16 subjects who discontinued routes of elimination would account for the pharmacokinetic differences observed in elderly subjects in this study (e.g. were in the high dose group and all 15 were due to adverse events. Of these 15 discontinuations, there were 4/8 subjects reduced clearance, higher concentrations, longer t 1/2,z compared with young subjects). Age-related pharmaco-(50%) aged between 18-45 years, 6/7 subjects (86%) aged 66-70 years, 4/5 subjects (80%) aged 71-75 years, and 1/1 kinetic differences were most evident during single dose assessment, but not during multiple dose assessment. The (100%) aged 76 years and over (Table 3 ). In the high dose group, 10/10 females (100%) dropped out compared with reason for this is unclear. To determine whether this might be an artifact of the high dropout rate in the elderly, as a 5/11 males (45%). result of differences in bioavailability affecting tolerability (i.e. subjects who had higher plasma concentrations would Discussion tend to drop out before multiple dose pharmacokinetic assessment, and thus reduce differences between age groups), Many drugs are less well tolerated in the elderly than in younger subjects. One reason for this may be age-related mean single dose pharmacokinetic parameters were compared between elderly subjects who dropped out of the changes in pharmacokinetics as a result of changes in renal or hepatic function or body composition [8] . Age-related study and for those who remained. However these were similar between the two groups. pharmacokinetic changes are most evident for compounds whose elimination is primarily by oxidative metabolism, but
In addition to single dose pharmacokinetic differences, felbamate was less well tolerated in elderly subjects in this not for compounds eliminated by glucuronidation, sulphation or acetylation [8, 9] . Such changes are of particular study compared with young subjects. Elderly subjects reported higher rates of adverse events and were more likely importance for antiepileptic drugs (AEDs), where oxidative metabolism is an important route of elimination for certain to drop out. Within the elderly subjects, there was a positive relationship between increasing age and incidence of adverse older compounds (e.g. carbamazepine, phenytoin), and whose therapeutic indices are low. Altered pharmacokinetics event reporting (for the low dose group) and with incidence of dropouts (for the high dose group). These observations have been reported in the elderly for most of the older AEDs [10] . For example, the elimination half-lives of may not only be associated with age-related pharmacokinetic differences, but may also indicate that the elderly are more phenytoin, valproate and carbamazepine are increased in elderly subjects compared with non-elderly adults; for the sensitive to the pharmacodynamic effects of felbamate than younger subjects. Similar findings have been reported for a latter two drugs, the magnitude of this change has been range of other compounds including AEDs [8, 9, 14] . The and multiple doses of 2400 mg day −1 [16] . As previously demonstrated [17] felbamate exhibits a linear relationship exact mechanisms underlying this increased sensitivity is unknown but may include altered receptor sensitivity, between dose and C max or AUC over the dose range of 1200-3600 mg day −1 . changes in second messenger activity, or impairment of general homeostatic mechanisms [8] . It should also be noted
In conclusion, felbamate pharmacokinetics and tolerability are different in elderly compared with young subjects. The that the rapid felbamate titration schedule in this study (doses were doubled over a 48 h period between Days 6 latter finding may be due to pharmacokinetic differences, or may also be due to increase sensitivity to the central effects and 8) complicates this issue. The dose titration schedule used in this study was based on a schedule used in an early of felbamate. Felbamate tolerability in the elderly may be enhanced if lower initial doses are used (e.g. 600 mg day −1 ) clinical study in patients with epilepsy [15] . More recent clinical studies as well as postmarketing experience have combined with more cautious titration (e.g. increase by 600 mg at intervals no shorter than every 1-2 weeks) than shown that the incidence of adverse events can be significantly reduced by using slower dose titration. Thus the present recommendations for administration to nonelderly subjects. the rapid titration of felbamate in the present study may have contributed to the poor tolerability seen in the young high dose group, and the poor tolerability in elderly low
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